Merck Serono to finance the launch of the EspeRare Foundation

Merck KGaAMerck Serono, a division of Merck, Darmstadt, Germany, today announced the launch of the EspeRare Foundation, a nonprofit organization set up by three Merck Serono employees, in the framework of the Merck Serono Entrepreneur Partnership Program (EPP). Merck Serono will donate an initial €2.8 million funding to the EspeRare Foundation. In addition, Merck Serono will transfer the rights of rimeporide, a compound previously developed for heart failure by Merck. The Foundation will investigate this compound in Duchenne Muscular Dystrophy (DMD), a lethal genetic rare disease affecting 1 in every 3 600 males.

"The EspeRare Foundation is the first initiative of its kind in the framework of the EPP. It is the result of our employees' determination to develop a unique operating model for the benefit of patients suffering from rare diseases, a field with high unmet needs and hardly no treatments available," said François Naef, Chairman of the Board of Directors of Merck Serono S.A. "The Foundation will play a central role by pioneering a collaborative system that brings together the right stakeholders to explore the therapeutic value of existing compounds, ultimately accelerating the R&D process in rare diseases."

The EspeRare Foundation's mission is to uncover the potential of existing drugs to address severe therapeutic unmet needs in rare diseases, through an established network of patient organizations, pharmaceutical companies, biotechs, regulators and academic institutions. The initial endowment from Merck Serono will enable the Foundation to start its activities with the development of rimeporide in DMD, while attracting additional private and public funding for this project and future repositioning programs in rare diseases.

The EspeRare Foundation was established by three Merck Serono employees: Caroline Kant, Florence Porte and Béatrice Greco. Sharon Terry, President and CEO of Genetic Alliance and an Executive Board Member of the International Rare Disease Research Consortium (IRDiRC), will join EspeRare as President of the Foundation.

"As a nonprofit organization, our priorities are not determined by commercial incentives or the size of a market, they are solely driven by the medical needs of patients suffering from rare diseases and the wealth of good science already available. We strive to apply our patient-centric model and our pharma R& D expertise to advance the discovery of new treatments for these underserved patients," commented Caroline Kant, Executive Director and Co-Founder of the EspeRare Foundation. "With our first program in Duchenne, our goal is to improve lives of young boys affected by this debilitating and fatal disease," she added.

Sharon Terry, President of the EspeRare Foundation, added: "The International Rare Disease Research Consortium has publicly and boldly declared that we, as a global community, will have 200 new drugs for rare diseases by 2020. The EspeRare Foundation has a great potential to become an important component in the new system that must be built to achieve this goal. The current pharma model needs to be adapted, new pathways are being forged and the Foundation will be a catalyst and incubator for a new way of addressing rare diseases."

The EspeRare Foundation will be presented to the public and to the international rare diseases community, at the first IRDiRC conference, taking place in Dublin, Ireland, on April 16-17, 2013.

The EspeRare Foundation is the seventh organization to benefit from the support of the Merck Serono EPP. Since 2012, this program has contributed to the successful creation of local biotech start-ups (Prexton Therapeutics, Asceneuron, Calypso Biotech) and service companies (Quartz Bio, TQM Insight, Ondaco). The EspeRare Foundation headquarters will be hosted in Eclosion, a public incubator for life sciences start-ups located in Plan-Les-Ouates, Geneva.

About the EspeRare Foundation EspeRare is a nonprofit private foundation established in Geneva, Switzerland in 2013. In collaboration with patient groups and other key stakeholders, the foundation strives to uncover the potential of existing drugs to address severe therapeutic unmet needs in rare diseases. Through the identification and translational validation of these ther apeutic opportunities, EspeRare focuses on giving better chances to already existing drug to reach rare diseases patients.

About the International Rare Diseases Research Consortium (IRDiRC)
The International Rare Diseases Research Consortium (IRDiRC) was initiated by the European Commission and the US National Institutes for Health Research and launched in April 2011 to foster international collaboration in the rare diseases field. IRDiRC will team up researchers and organizations investing in rare diseases research in order to achieve two main objectives, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases by the year 2020.

About Merck Serono
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono. Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

About Merck
Merck is a leading pharmaceutical, chemical and life science company with total revenues of € 11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 39,000 employees in 66 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.